You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethsuximide
Accession NumberDB05246
TypeSmall Molecule
GroupsApproved
DescriptionMesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]
Structure
Thumb
Synonyms
(RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion
1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine
1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione
1,3-Dimethyl-3-phenylsuccinimide
Alpha-methyl-alpha-phenyl n-methyl succinimide
Alpha-methylphensuximide
Celontin
Mesuximida
Mesuximide
Mesuximidum
Methsuximid
Metosuccimmide
Metsuccimide
N-methyl-alpha-methyl-alpha-phenylsuccinimide
N,2-Dimethyl-2-phenylsuccinimide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CelontinCapsule300 mg/1OralParke Davis Div Of Pfizer Inc1957-02-08Not applicableUs
Celontin Cap 300mgCapsule300 mgOralErfa Canada 2012 Inc1957-12-312015-06-05Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PetinutinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0G76K8X6C0
CAS number77-41-8
WeightAverage: 203.2371
Monoisotopic: 203.094628665
Chemical FormulaC12H13NO2
InChI KeyAJXPJJZHWIXJCJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
IUPAC Name
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
SMILES
CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
Pharmacology
IndicationFor the control of absence (petit mal) seizures that are refractory to other drugs.
Structured Indications
PharmacodynamicsUsed in the treatment of epilepsy. Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Mechanism of actionBinds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent T-type calcium channel subunit alpha-1GProteinyes
inhibitor
HumanO43497 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.
ClearanceNot Available
ToxicityAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methsuximide.Experimental
AbirateroneThe metabolism of Methsuximide can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methsuximide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methsuximide.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Methsuximide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methsuximide.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methsuximide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methsuximide.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methsuximide.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methsuximide.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methsuximide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methsuximide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methsuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methsuximide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.Approved, Investigational
ArmodafinilThe metabolism of Methsuximide can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Methsuximide.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methsuximide.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methsuximide.Vet Approved
AzelastineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methsuximide.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methsuximide.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methsuximide.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methsuximide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methsuximide.Approved
BortezomibThe metabolism of Methsuximide can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Methsuximide.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Methsuximide.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methsuximide.Approved, Investigational
BuprenorphineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Methsuximide.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methsuximide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Methsuximide.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methsuximide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Methsuximide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methsuximide.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methsuximide.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Methsuximide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methsuximide.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methsuximide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methsuximide.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.Approved
CholecalciferolThe metabolism of Methsuximide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Methsuximide.Approved
CimetidineThe metabolism of Methsuximide can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methsuximide.Approved, Vet Approved
CitalopramThe metabolism of Methsuximide can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methsuximide.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Methsuximide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methsuximide.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.Approved, Illicit
ClotrimazoleThe metabolism of Methsuximide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methsuximide.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methsuximide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.Approved
DabrafenibThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methsuximide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.Investigational
DelavirdineThe metabolism of Methsuximide can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Methsuximide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Methsuximide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methsuximide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methsuximide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methsuximide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methsuximide.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Methsuximide.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methsuximide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methsuximide.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Methsuximide.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methsuximide.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methsuximide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methsuximide.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methsuximide.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methsuximide.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methsuximide.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Methsuximide can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Methsuximide can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.Approved
EthanolMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methsuximide.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methsuximide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methsuximide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Methsuximide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Methsuximide.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Methsuximide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methsuximide.Illicit, Vet Approved
EtravirineThe metabolism of Methsuximide can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Methsuximide.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methsuximide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methsuximide.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.Approved
FluconazoleThe metabolism of Methsuximide can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methsuximide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methsuximide.Approved, Illicit
FluoxetineThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methsuximide.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Methsuximide.Approved
FluvoxamineThe metabolism of Methsuximide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Methsuximide can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methsuximide.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methsuximide is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methsuximide.Approved, Illicit
GemfibrozilThe metabolism of Methsuximide can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methsuximide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methsuximide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methsuximide.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methsuximide.Approved
HydrocodoneMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Methsuximide can be decreased when combined with Indinavir.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methsuximide.Approved, Vet Approved
IsoniazidThe metabolism of Methsuximide can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methsuximide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methsuximide.Approved
KetoconazoleThe metabolism of Methsuximide can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methsuximide.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methsuximide.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methsuximide.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methsuximide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methsuximide.Illicit
LopinavirThe metabolism of Methsuximide can be increased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methsuximide.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Methsuximide.Investigational
LuliconazoleThe serum concentration of Methsuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methsuximide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Methsuximide.Vet Approved
MefloquineThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methsuximide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methsuximide.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methsuximide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methsuximide.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methsuximide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methsuximide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methsuximide.Approved
MethotrimeprazineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methsuximide.Approved, Vet Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methsuximide.Approved
MetyrosineMethsuximide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
MirtazapineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Methsuximide can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Methsuximide can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Methsuximide can be decreased when combined with Nelfinavir.Approved
NicardipineThe metabolism of Methsuximide can be decreased when combined with Nicardipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methsuximide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methsuximide.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methsuximide.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.Approved
OmeprazoleThe metabolism of Methsuximide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methsuximide.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methsuximide.Approved, Illicit
OrlistatThe serum concentration of Methsuximide can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methsuximide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methsuximide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methsuximide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.Approved
PantoprazoleThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.Approved
ParaldehydeMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methsuximide.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methsuximide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methsuximide.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Methsuximide.Approved
PhenytoinThe metabolism of Methsuximide can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methsuximide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
PramipexoleMethsuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methsuximide.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methsuximide.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methsuximide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methsuximide.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methsuximide.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methsuximide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Methsuximide.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Methsuximide.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.Approved
RifampicinThe metabolism of Methsuximide can be increased when combined with Rifampicin.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Methsuximide.Vet Approved
RopiniroleMethsuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide.Approved
RotigotineMethsuximide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methsuximide.Experimental
Sage 547The risk or severity of adverse effects can be increased when Methsuximide is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methsuximide.Approved, Withdrawn
SertralineThe metabolism of Methsuximide can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
StiripentolThe metabolism of Methsuximide can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.Approved
SuvorexantMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methsuximide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methsuximide.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methsuximide.Investigational
ThalidomideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methsuximide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methsuximide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methsuximide.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tiapride.Investigational
TiclopidineThe metabolism of Methsuximide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Methsuximide.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methsuximide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methsuximide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methsuximide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methsuximide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.Approved
Uc1010The risk or severity of adverse effects can be increased when Methsuximide is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methsuximide.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.Approved
VoriconazoleThe metabolism of Methsuximide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methsuximide.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Methsuximide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Methsuximide.Vet Approved
ZolpidemMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methsuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methsuximide.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food
References
Synthesis ReferenceNot Available
General References
  1. Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. [PubMed:8777552 ]
  2. Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [PubMed:10802770 ]
External Links
ATC CodesN03AD03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9967
Caco-2 permeable+0.6968
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8599
P-glycoprotein inhibitor IINon-inhibitor0.9433
Renal organic cation transporterNon-inhibitor0.7784
CYP450 2C9 substrateNon-substrate0.7943
CYP450 2D6 substrateNon-substrate0.8923
CYP450 3A4 substrateSubstrate0.6004
CYP450 1A2 substrateNon-inhibitor0.888
CYP450 2C9 inhibitorNon-inhibitor0.8882
CYP450 2D6 inhibitorNon-inhibitor0.922
CYP450 2C19 inhibitorNon-inhibitor0.845
CYP450 3A4 inhibitorNon-inhibitor0.9748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9629
Ames testNon AMES toxic0.9099
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.8265
Rat acute toxicity2.1961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Non-inhibitor0.9625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral300 mg/1
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Celontin 300 mg kapseal1.53USD each
Celontin 300 mg Capsule1.1USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point52.5 °CPhysProp
boiling point121.5 °C at 1.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.13 mg/mLALOGPS
logP1.46ALOGPS
logP1.46ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.35 m3·mol-1ChemAxon
Polarizability21.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014i-4910000000-aa3742fc04cdbcda351fView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolidines
Sub ClassPhenylpyrrolidines
Direct ParentPhenylpyrrolidines
Alternative Parents
Substituents
  • 3-phenylpyrrolidine
  • Dicarboximide
  • Benzenoid
  • N-alkylpyrrolidine
  • 2-pyrrolidone
  • Pyrrolidone
  • Carboxylic acid imide, n-substituted
  • Monocyclic benzene moiety
  • Pyrrole
  • Carboxylic acid imide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441 ]
  2. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161 ]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061 ]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on October 30, 2007 19:03 / Updated on August 17, 2016 12:24